Business Model Breakdown
How Myomo Inc Makes Money
MYO
Market Cap
$54M
Annual Revenue
$41M
Profit Margin
-36.7%
Employees
184
The Short Version
Myomo Inc. designs, manufactures, and markets MyoPro, a line of wearable robotic orthotics (braces) specifically developed for individuals with neurological disorders such as stroke, spinal cord injury, or ALS. These FDA-cleared, myoelectric-controlled devices use signals from the user's muscles to help restore function and movement to weakened or paralyzed arms and hands. The company generates revenue primarily through the direct sale or rental of these advanced medical devices, often working with clinicians and rehabilitation centers, and by navigating complex insurance and government reimbursement pathways (like Medicare) to make its technology accessible to patients. Recently, strategic partnerships, such as with Ottobock, are expanding its global distribution footprint.
Where the Revenue Comes From
Direct sales and rentals of MyoPro devices (primary contributor)
Related services (e.g., training, maintenance, support)
Revenue through distribution partnerships (e.g., Ottobock)
Who buys: Individuals suffering from neurological disorders (e.g., stroke, spinal cord injury, ALS patients), rehabilitation clinics, hospitals, and medical device distributors.
Why It Works (Competitive Advantages)
- ✔Proprietary technology and intellectual property (MyoPro 2+)
- ✔Established regulatory clearances (FDA, CPT codes) and reimbursement pathways (Medicare coverage)
- ✔Strategic distribution partnership with Ottobock, a leading orthotics and prosthetics company
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs, Regulatory Advantages)
What Our Analysis Says
DVR Score as of June 12, 2026
Myomo continues to address a large, underserved neurological rehabilitation market with its MyoPro device, validated by strong regulatory clearances and expanding reimbursement. Q1 2026 results, reported on May 9, 2026, exceeded consensus estimates with $10.1M revenue and narrower EPS loss of ($0.07), building on previous operational improvements. The formalization of Horton Capital's 6.0% stake and board representation, coupled with recent insider buying by Director Kirk, signals strengthening institutional confidence and strategic oversight. The unanimous Buy rating from analysts with a median price target of $7.67 (implying ~5.6x upside) further supports a positive outlook. However, the company still faces significant financial challenges, including persistent net losses (TTM -$15.12M), continued cash burn, and a balance sheet that likely necessitates future funding. While operational execution shows signs of improvement, the path to sustained profitability and substantial revenue acceleration for 10x growth remains high-risk and requires careful monitoring of cash flow and dilution.